Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS. (Q43706014)

26 November 2017

Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS. (English)

1 reference

26 November 2017

0 references

0 references

1 reference

10

1 reference

26 November 2017

11

Nathalie Cordonnier

1 reference

26 November 2017

Bernard Klonjkowski

1

1 reference

26 November 2017

Dieter Klein

2

1 reference

26 November 2017

Sandra Galea

3

1 reference

26 November 2017

Françoise Gavard

4

1 reference

26 November 2017

Martine Monteil

5

1 reference

26 November 2017

Lidia Duarte

6

1 reference

26 November 2017

Annie Fournier

7

1 reference

26 November 2017

Sophie Sayon

8

1 reference

26 November 2017

Kamila Górna

9

1 reference

26 November 2017

Pierre Sonigo

12

1 reference

26 November 2017

Marc Eloit

13

1 reference

26 November 2017

Jennifer Richardson

14

1 reference

26 November 2017

language of work or name

English

0 references

publication date

12 December 2008

1 reference

26 November 2017

12

1 reference

inferred from page(s)

published in

Vaccine

1 reference

26 November 2017

27

1 reference

26 November 2017

6

1 reference

26 November 2017

928-939

1 reference

Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

The history of simian AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Use of CD134 as a primary receptor by the feline immunodeficiency virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Antibodies, viruses and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Adenoviral vectors for mucosal vaccination against infectious diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Adenoviruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

The innate immune response to adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Current strategies and future directions for eluding adenoviral vector immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Development of nonhuman adenoviruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Characteristics of a human cell line transformed by DNA from human adenovirus type 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

In vitro properties and experimental pathogenic effect of three strains of feline immunodeficiency viruses (FIV) isolated from cats with terminal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Immunodiagnosis of feline immunodeficiency virus infection using recombinant viral p17 and p24

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Expression of the Foot-and-Mouth Disease Virus VP1 protein using a replication-competent recombinant canine adenovirus type 2 elicits a humoral antibody response in a porcine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Complete protection of cats against feline panleukopenia virus challenge by a recombinant canine adenovirus type 2 expressing VP2 from FPV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Antibody-dependent enhancement and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Concurrent infections and HIV pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

A study of HIV RNA viral load in AIDS patients with bacterial pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Increase in plasma viral load after oral cholera immunization of HIV-infected subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Activation of virus replication after vaccination of HIV-1-infected individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Lymphoid activation: a confounding factor in AIDS vaccine development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Enhancement after feline immunodeficiency virus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Vaccination with a T-cell-priming Gag peptide of caprine arthritis encephalitis virus enhances virus replication transiently in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Vaccination of sheep with Maedi-visna virus gag gene and protein, beneficial or harmful?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

HIV preferentially infects HIV-specific CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Potential pitfalls on the road to an effective HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

HIV vaccine failure prompts Merck to halt trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

AIDS research. Promising AIDS vaccine's failure leaves field reeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

HIV vaccine may raise risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Antipeptide antisera define neutralizing epitopes on the adenovirus hexon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

HIV-1 T-cell vaccines: evaluating the next step

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

Perils at mucosal front lines for HIV and SIV and their hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

In vivo lymphocyte tropism of feline immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

7 January 2021

Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

7 January 2021

B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

7 January 2021

Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

7 January 2021

Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.086

7 January 2021

10.1016/J.VACCINE.2008.11.086

Identifiers

DOI

1 reference

26 November 2017

1 reference